EKF Diagnostics said this week that it will launch its PointMan DNA enrichment kits at the American Society for Clinical Oncology meeting later this month in Chicago.
The company is commercializing three kits to enrich mutations in BRAF, KRAS, and EGFR T790M genes associated with melanoma, colorectal, and lung cancers. According to the company, PointMan kits offer highly specific and ultra-sensitive enrichment of mutant genes in a background of wild-type genes that is "unmatched" by existing technologies.
PointMan is a real-time PCR technology that is highly efficient in amplifying a target sequence of interest while suppressing amplification of wild-type sequences. The kits can be used to enrich all mutant sequences within a gene of interest using a single set of reagents, as opposed to requiring a separate reagents set for each mutation.
This will be the first product introduction by EKF since it acquired 360 Genomics and established EKF Molecular Diagnostics in March.